Greenfield Seitz Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Greenfield Seitz Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.92M	Buy	3,074 +60	+2%	+$40.8K	0.57%	45
2026 Q1	$2.33M	Buy	3,014 +51	+2%	+$39K	0.7%	43
2025 Q4	$2.29M	Sell	2,963 -297	-9%	-$202K	0.75%	43
2025 Q3	$1.83M	Buy	3,260 +46	+1%	+$26K	0.59%	47
2025 Q2	$1.69M	Buy	3,214 +192	+6%	+$107K	0.6%	44
2025 Q1	$1.92M	Buy	3,022 +298	+11%	+$205K	0.73%	40
2024 Q4	$1.94M	Buy	2,724 +373	+16%	+$313K	0.74%	39
2024 Q3	$2.47M	Sell	2,351 -24	-1%	-$26.7K	0.91%	36
2024 Q2	$2.5M	Buy	2,375 +6	+0.3%	+$5.82K	0.92%	38
2024 Q1	$2.28M	Buy	2,369 +171	+8%	+$163K	0.85%	39
2023 Q4	$1.93M	Buy	+2,198	New	+$1.81M	0.77%	40

Other funds holding REGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Greenfield Seitz Capital Management's REGN Position: Q2 2026 in Review

Greenfield Seitz Capital Management increased its Regeneron Pharmaceuticals (REGN) stake by 2% in Q2 2026, buying an estimated $40.8K and bringing the position to 3,074 shares worth $1.92M. The position accounts for 0.57% of the portfolio, ranked #45.

Greenfield Seitz Capital Management first reported a position in REGN in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.5M in Q2 2024. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

Greenfield Seitz Capital Management held 3,074 shares of Regeneron Pharmaceuticals worth $1.92M as of Q2 2026.
Greenfield Seitz Capital Management bought 60 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $40.8K.
Regeneron Pharmaceuticals made up 0.57% of Greenfield Seitz Capital Management's portfolio in Q2 2026, its #45 holding.
Greenfield Seitz Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Greenfield Seitz Capital Management's Regeneron Pharmaceuticals position peaked at $2.5M in Q2 2024.
1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Greenfield Seitz Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.